INT275940

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.39
First Reported 2008
Last Reported 2009
Negated 0
Speculated 1
Reported most in Body
Documents 3
Total Number 6
Disease Relevance 2.08
Pain Relevance 0.95

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

kinase activity (Syk) cytoplasm (Syk)
Syk (Mus musculus)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 195 99.56 Very High Very High Very High
Arthritis 192 98.68 Very High Very High Very High
Inflammation 145 95.88 Very High Very High Very High
Central nervous system 3 79.08 Quite High
chemokine 12 77.84 Quite High
cytokine 65 76.64 Quite High
agonist 13 34.72 Quite Low
Inflammatory response 17 5.00 Very Low Very Low Very Low
methotrexate 12 5.00 Very Low Very Low Very Low
Inflammatory mediators 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 195 99.56 Very High Very High Very High
Arthritis 186 98.68 Very High Very High Very High
Autoimmune Disease 6 96.76 Very High Very High Very High
Synovitis 3 96.72 Very High Very High Very High
Thrombosis 1 91.56 High High
Hemorrhage 1 90.28 High High
INFLAMMATION 79 88.60 High High
Nervous System Inflammation 3 79.60 Quite High
Neutropenia 6 77.80 Quite High
Diarrhoea 3 77.12 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We showed that specific inhibition of Syk blocked the Hz-induced cathepsin B activation.
Negative_regulation (inhibition) of Syk
1) Confidence 0.39 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2722371 Disease Relevance 0 Pain Relevance 0
To test whether the PI3K pathway is required for propagation of the Syk signaling pathway following Hz exposure, the PI3K inhibitor wortmannin was used prior to Hz stimulation.
Spec (whether) Negative_regulation (propagation) of Syk
2) Confidence 0.28 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2722371 Disease Relevance 0 Pain Relevance 0
This reduction is most likely due to increased accessibility of tyrosine residues in Syk to protein tyrosine phosphatases in the absence of LAT.
Negative_regulation (accessibility) of Syk
3) Confidence 0.24 Published 2008 Journal Journal of Thrombosis and Haemostasis Section Body Doc Link PMC2710801 Disease Relevance 0.18 Pain Relevance 0
However, it remains to be determined as to the extent that R406 can be continuously employed in the treatment of chronic RA, the extent to which reduced levels of SyK are maintained by administration of R406 and whether R406 therapy will show a sustained improvement in arthritis symptoms compared to that obtained with conventional or biologic DMARDs.

5.

Negative_regulation (reduced) of SyK associated with rheumatoid arthritis and arthritis
4) Confidence 0.20 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2842969 Disease Relevance 0.56 Pain Relevance 0.25
At the experimental level, Pine et al. [68] showed that R788 a prodrug of the active novel SyK small molecule inhibitor R406 suppressed the severity of arthritis, bone erosions, pannus development and synovitis in murine collagen-induced arthritis (CIA).
Negative_regulation (inhibitor) of SyK associated with synovitis and arthritis
5) Confidence 0.20 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2842969 Disease Relevance 0.83 Pain Relevance 0.46
Of note, since Cbl ubiquitin ligase was previously shown to be a negative regulator of Syk [64], various experimental attempts have been made to limit SyK activation through targeting of the polyubquitination-proteasome pathway [65, 66].
Negative_regulation (regulator) of Syk
6) Confidence 0.20 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2842969 Disease Relevance 0.52 Pain Relevance 0.24

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox